| 000 | 01728 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516074033.0 | ||
| 264 | 0 | _c20120919 | |
| 008 | 201209s 0 0 eng d | ||
| 022 | _a1463-1326 | ||
| 024 | 7 |
_a10.1111/j.1463-1326.2012.01567.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPendergrass, M | |
| 245 | 0 | 0 |
_aExenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. _h[electronic resource] |
| 260 |
_bDiabetes, obesity & metabolism _cJul 2012 |
||
| 300 |
_a596-600 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcute Kidney Injury _xchemically induced |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xcomplications |
| 650 | 0 | 4 |
_aDipeptidyl-Peptidase IV Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Labeling |
| 650 | 0 | 4 | _aExenatide |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPeptides _xadministration & dosage |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 |
_aPyrazines _xadministration & dosage |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aSitagliptin Phosphate |
| 650 | 0 | 4 |
_aTriazoles _xadministration & dosage |
| 650 | 0 | 4 |
_aVenoms _xadministration & dosage |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aFenton, C | |
| 700 | 1 | _aHaffner, S M | |
| 700 | 1 | _aChen, W | |
| 773 | 0 |
_tDiabetes, obesity & metabolism _gvol. 14 _gno. 7 _gp. 596-600 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1463-1326.2012.01567.x _zAvailable from publisher's website |
| 999 |
_c21483285 _d21483285 |
||